Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Bacterial Reduction on Skin Flora Post-product Application
Interventions: ChloraPrep Hi-Lite Orange, Normal saline, 3M CHG/IPA Prep Tint 10.5-mL, 3M CHG/IPA Prep Tint 26-mL; Drug
Lead sponsor: Solventum US LLC; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sterling, Virginia

Conditions: Chronic Testicular Pain
Interventions: Botox Injection, Normal saline injection; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
Interventions: OnabotulinumtoxinA, Placebo (Normal Saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Mountlake Terrace, Washington

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Osteoarthritis Knee Pain
Interventions: SL1002, Normal Saline; Drug
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Roseville, California • San Diego, California • Greenwood Village, Colorado + 19 more

Conditions: Back Pain Lower Back Chronic
Interventions: Saline, Dextrose; Drug
Lead sponsor: Smigel, Liza, M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Hilo, Hawaii

Conditions: Degenerative Osteoarthritis
Interventions: TG-C, Placebo Control; Biological
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 27
States / cities: Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more

Conditions: Hemorrhagic Shock
Interventions: Glutamine, Ringer's Lactate, Placebo (for Glutamine); Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 21 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Migraine Headache
Interventions: bupivicaine, normal saline, methylprednisolone, lidocaine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cerebrovascular Accident
Interventions: GSK249320 100/mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more

Conditions: Acute Kidney Injury
Interventions: 0.9% sodium chloride, Physiologically balanced fluid; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pain, Postoperative
Interventions: Combined Bupivacaine and Exparel, Normal Saline (NS); Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension, Resistant to Conventional Therapy
Interventions: Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Erythema
Interventions: MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Mucinous Pancreatic Cysts
Interventions: Ethanol, Normal Saline, Chemotherapy; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
Interventions: AB103 0.5 mg/kg, NaCl 0.9%; Drug · Other
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions: Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline; Drug · Procedure
Lead sponsor: Lauren Giugale, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions: BR-AC, Standard Care; Other
Lead sponsor: BioStem Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more

Conditions: Aging
Interventions: Ascorbic Acid, Normal Saline; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 79 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Surgical Wound Infections
Interventions: Vancomycin, Placebo (Saline Solution); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Open Fracture Wounds
Interventions: Saline Solution, Soap solution, Gravity Flow Irrigation, Low Pressure Irrigation, High Pressure; Procedure
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 14 Years to 85 Years
Enrollment: 2,540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 11 more

Conditions: Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis, Late-Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Death; Neonatal
Interventions: Ampicillin, Gentamycin, Normal saline; Drug
Lead sponsor: Michael Morowitz; Other
Eligibility: Up to 4 Hours
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Mobile, Alabama • San Diego, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

In-vivo Efficacy Study of Patient Pre-operative Preps

Botulinum Toxin for the Management of Chronic Orchialgia

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

Caudal Epidural Injection of Dextrose For Low Back Pain

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

Greater Occipital Nerve Block for Migraine Prophylaxis

Proof of Concept (POC) in Patients With Ischaemic Stroke

Isotonic Solution Administration Logistical Testing

Long-acting Local Vaginal Cuff Anesthesia Following Hysterectomy

MANP in African Americans With Hypertension

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

Mechanisms of Impaired Brain Blood Flow With Aging

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Prevention of Neurosurgical Wound Infections

Fluid Lavage of Open Wounds

NICU Antibiotics and Outcomes Trial